MDWD - MediWound's EscharEx treatment meets main goal in mid-stage trial

MediWound (MDWD) said that its wound debriding product candidate EscharEx met the main goal in a mid-stage trial in patients with a variety of chronic and hard-to-heal wounds.The company announces that a peer-reviewed publication, detailing the results of the phase 2 randomized control trial of EscharEx has been published in the Wound Repair and Regeneration Journal.The EscharEx arm achieved a "significantly higher" incidence of complete debridement compared to the gel vehicle arm, meeting the primary endpoint of the study, the company said.Both arms achieved similar reductions in wound area, non-viable tissue area, and wound healing scores during the debridement period.There were no significant differences between the arms in the incidence of complete wound closure and in the mean time to complete wound closure, and no significant safety issues were observed."The data clearly demonstrate that EscharEx debrides severe wounds rapidly and effectively with no deleterious effect on wound healing," CEO Sharon Malka said.The company also highlighted

For further details see:

MediWound's EscharEx treatment meets main goal in mid-stage trial